- Conditions
- Endometrial Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Uterine Corpus Cancer, Stage IIIC1 Uterine Corpus Cancer, Stage IIIC2 Uterine Corpus Cancer, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer
- Interventions
- Laboratory Biomarker Analysis, Megestrol Acetate, Tamoxifen Citrate, Temsirolimus
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Female only
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 108
- States / cities
- Burbank, California • Palo Alto, California • San Diego, California + 75 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 38
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Anorexia, Cachexia, Weight Loss
- Interventions
- Megestrol acetate concentrated suspension 110 mg/mL, Placebo
- Drug
- Lead sponsor
- Par Pharmaceutical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 3
- States / cities
- Miami, Florida • Cumberland, Maryland • Mt. Pleasant, South Carolina
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific, Weight Changes
- Interventions
- Megestrol Acetate, Oxandrolone 20 mg
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 20
- States / cities
- Newark, Delaware • Miami Beach, Florida • Louisville, Kentucky + 16 more
- Conditions
- Chronic Oral Food Refusal
- Interventions
- Amitriptyline, Placebo, Megestrol
- Drug
- Lead sponsor
- Ann Davis, PhD, MPH, ABPP
- Other
- Eligibility
- 9 Months to 8 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2014
- U.S. locations
- 3
- States / cities
- Kansas City, Kansas • New Orleans, Louisiana • Columbus, Ohio
- Conditions
- Anorexia, Cachexia, Head and Neck Cancer, Quality of Life
- Interventions
- megestrol acetate, quality-of-life assessment
- Drug · Procedure
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Anorexia, Cachexia, Weight Loss
- Interventions
- Megestrol acetate concentrated suspension 110 mg/mL, Megestrol acetate concentrated suspension 60 mg/mL, Placebo
- Drug
- Lead sponsor
- Par Pharmaceutical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 4
- States / cities
- Anaheim, California • Flat Rock, North Carolina • High Point, North Carolina + 1 more
- Conditions
- Adrenal Insufficiency
- Interventions
- megestrol acetate
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 65 Years to 80 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Breast Cancer
- Interventions
- filgrastim, cyclophosphamide, megestrol acetate, melphalan, tamoxifen citrate, thiotepa, conventional surgery, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2000
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Brain Tumor, Central Nervous System Tumors, Cachexia, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- cyproheptadine hydrochloride, megestrol acetate
- Drug
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 2 Years to 20 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 40
- States / cities
- Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 33 more
- Conditions
- Endometrial Endometrioid Adenocarcinoma, Endometrial Hyperplasia
- Interventions
- Biopsy Procedure, Curettage Procedure, Hysterectomy, Megestrol Acetate, Progesterone Only Hormone Replacement Therapy
- Procedure · Drug
- Lead sponsor
- New Mexico Cancer Research Alliance
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 4
- States / cities
- Iowa City, Iowa • Albuquerque, New Mexico • Salt Lake City, Utah + 1 more
- Conditions
- Recurrent or Persistent Endometrial Carcinoma
- Interventions
- Sodium cridanimod
- Drug
- Lead sponsor
- Kevelt AS
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 4
- States / cities
- San Jose, California • Santa Rosa, California • Detroit, Michigan + 1 more
- Conditions
- Carcinoma
- Interventions
- Everolimus, Everolimus Placebo, Best Supportive Care (BSC)
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 546 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 19
- States / cities
- Fayetteville, Arkansas • Fountain Valley, California • La Jolla, California + 15 more
- Conditions
- Healthy
- Interventions
- Megestrol acetate concentrated suspension 125 mg/mL
- Drug
- Lead sponsor
- Par Pharmaceutical, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Atypical Endometrial Hyperplasia, Endometrial Carcinoma
- Interventions
- Megestrol Acetate
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Anorexia, Cachexia, Lung Cancer
- Interventions
- megestrol acetate, radiation therapy
- Drug · Radiation
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Cachexia
- Interventions
- transdermal Megace
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Anorexia, Cachexia
- Interventions
- eicosapentaenoic acid, megestrol acetate, placebo
- Dietary Supplement · Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 429 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 22
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 19 more
- Conditions
- Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Carcinoma
- Interventions
- Biopsy Procedure, Extended Release Metformin Hydrochloride, Megestrol Acetate, Questionnaire Administration
- Procedure · Drug · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Denver, Colorado • Chicago, Illinois + 5 more
- Conditions
- Cognitive Impairment
- Interventions
- Phenytoin 200 mg capsule, Megestrol 800 mg liquid, Phenytoin-matched Placebo capsule, Megestrol-matched liquid Placebo
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- High Grade Squamous Intraepithelial Neoplasia, Stage 0 Uterine Corpus Cancer
- Interventions
- Biopsy, Laboratory Biomarker Analysis, Megestrol Acetate, Pharmacological Study, Quality-of-Life Assessment, Therapeutic Conventional Surgery
- Procedure · Other · Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 50
- States / cities
- Los Angeles, California • Sylmar, California • Hartford, Connecticut + 34 more
- Conditions
- Endometrial Cancer
- Interventions
- Sodium Cridanimod, progestin therapy
- Drug
- Lead sponsor
- Xenetic Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 25
- States / cities
- Burbank, California • Irvine, California • Los Angeles, California + 22 more
- Conditions
- Malignant Neoplasm
- Interventions
- Opevesostat, Fludrocortisone/ Fludrocortisone acetate, Dexamethasone/Dexamethasone acetate, Rescue Medications, Fulvestrant, Exemestane, Megestrol acetate/Medroxyprogesterone acetate, Tamoxifen, Letrozole
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 10
- States / cities
- Anchorage, Alaska • Miami Beach, Florida • Shreveport, Louisiana + 6 more
- Conditions
- FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Metastatic Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, Ipatasertib, Magnetic Resonance Imaging, Megestrol Acetate
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 152
- States / cities
- Tucson, Arizona • Fayetteville, Arkansas • Rogers, Arkansas + 119 more
- Conditions
- Feeding Behavior, Feeding Disorder of Infancy or Early Childhood
- Interventions
- Megestrol Acetate, iKanEat Behavioral Intervention
- Drug · Behavioral
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 9 Months to 108 Months
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2025
- U.S. locations
- 8
- States / cities
- San Diego, California • Orlando, Florida • Indianapolis, Indiana + 5 more